|
|
|
| Study on transdermal absorption and anti-inflammatory activity of Compound Sanguis Draxonis Microemulsion in vitro |
| DANG Xueliang1 JIA Lihua2 SONG Yanfeng1 ZHAO Jun1 WANG Qingwei1 |
1.Department of Pharmacy, the Second Affiliated Hospital of Air Force Medical University, Shaanxi Province, Xi′an 710038, China;
2.Shaanxi Institute for Food and Drug Control, Shaanxi Province, Xi′an 710065, China; |
|
|
|
Abstract Objective To investigate the transdermal absorption of main active components of Compound Sanguis Draxonis Microemulsion with different concentrations in vitro, and provide experimental basis for further study of the preparation. Methods According to the random number table, twenty-four SD rats were randomly divided into 3 groups, which were high-dose group (5.0%), medium-dose group (2.5%) and low-dose group (1.0%) of Compound Sanguis Draxonis Microemulsion, with 8 rats in each group. The isolated rat skin of the same part was taken as the permeation barrier, and the content of ligustilide, the main active ingredient of Compound Sanguis Draxonis Microemulsion, was determined by HPLC using modified Franz diffusion cell. The transdermal absorption of Compound Sanguis Draxonis Microemulsion was investigated by calculating the cumulative permeation amount of ligustilide in vitro. Forty SD rats were randomly divided into 5 groups according to their body weight, which were model group, Dexamethasone Acetate Cream group, high-dose group (5.0%), medium-dose group (2.5%) and low-dose group (1.0%) of Compound Sanguis Draxonis Microemulsion with 8 rats in each group. Experiment of paw swelling in rats induced by carrageenan was operated to observe inflammation inhibited by Compound Sanguis Draxonis Microemulsion, Dexamethasone Acetate Cream group as positive control group. Results The cumulative permeabilities of ligustilide, the main active ingredient of low-dose, medium-dose and high-dose groups of Compound Sanguis Draxonis Microemulsion, within 24 h were (153.000±6.586), (311.200±14.520) and (454.100±23.440) μg/cm2 respectively. The transdermal rate constants Jss were (6.8130±0.2196), (13.7100±0.5953), (20.1900±0.9491) μg/(cm2·h), respectively. Compared with the positive control group, the high-dose group of Compound Sanguis Draxonis Microemulsion significantly inhibited carrageenan-induced paw swelling in rats (P ＜ 0.01). Conclusion Compound Sanguis Draxonis Microemulsion has good transdermal performance and anti-inflammatory activity in vitro. The cumulative permeability per unit area within 24 h increased with the content of ligustilide, and the transdermal permeation behavior conformed to the zero-order kinetic equation.
|
|
|
|
|
|
[1] 刘梅，党学良，王庆伟，等.复方血竭微乳对豚鼠皮肤刺激性实验观察[J].中国医药导报，2011，8（31）：15-16.
[2] 陈振鹤，吴国泰，孙敏，等.当归中藁本内酯研究概况[J].甘肃中医药大学学报，2018，35（2）：102-105.
[3] 李海刚，胡晒平，周意，等.川芎主要药理活性成分药理研究进展[J].中国临床药理学与治疗学，2018，23（11）：1302-1308.
[4] 张旸，王庆伟，赵欢欢，等.复方根皮素乳膏中根皮素、藁本内酯体外透皮吸收研究[J].中国药师，2017，20（6）：1038-1041.
[5] 朱小芳，罗晶，管咏梅，等.乳香没药挥发油对川芎体外透皮吸收的影响及其皮肤血流促透机制研究[J].中国中药杂志，2017，42（4）：680-685.
[6] 张旸，王庆伟，赵欢欢，等.复方根皮素乳膏中根皮素、藁本内酯体外透皮吸收研究[J].中国药师，2017，20（6）：1038-1041.
[7] 乔元，张京，徐媛，等.当归挥发油的透皮特性及其作用机制研究[J].中国药师，2017，20（3）：421-426.
[8] 朱小芳，罗晶，管咏梅，等.乳香没药挥发油对川芎体外透皮吸收的影响及其皮肤血流促透机制研究[J].中国中药杂志，2017，42（4）：680-685.
[9] 王艳宏，刘书博，王锐，等.中药挥发油促透皮吸收及透皮吸收作用的研究进展[J].中国实验方剂学杂志，2017， 23（3）：192-199.
[10] 党学良，赵军，李晰，等.不同促透剂对Ex-RAD凝胶体外透皮吸收的影响[J].医药导报，2016，35（10）：1050-1054.
[11] 阮毅铭，彭伟文，梅全喜，等.漆大姑抗炎、抗过敏和止痒作用研究[J].中药药理与临床，2017，33（5）：108-111.
[12] 徐杰，姜文月，李敏，等.颈腰康胶囊药效学研究[J].亚太传统医药，2018，14（9）：20-22.
[13] 田建明，韦康，陈英红，等.人参糖肽对大鼠的抗炎和镇痛作用[J].中国新药杂志，2018，27（14）：1658-1662.
[14] 杨欢，程笑，王月华，等.秦皮甲素对角叉菜胶致小鼠足肿胀及炎症的作用[J].中国新药杂志，2016，25（20）：2319-2322.
[15] 崔晓燕，王素霞，候永利.金银花提取物的抗炎机制研究[J].中国药房，2007，18（24）：1861-1863.
[16] 刘安韬，张婷，梁红，等.皂布叶提取物抗痛风作用研究[J].中国医药科学，2017，7（17）：40-42，68.
[17] 姚淞允，张开霞，马强，等.藁本内酯的临床前研究进展[J].药学服务与研究，2019，19（2）：106-110.
[18] 胡碧薇，初杰.藁本内酯实验研究进展[J].辽宁中医药大学学报，2014，16（1）：215-217.
[19] 张来宾，吕洁丽，陈红丽，等.当归中苯酞类成分及其药理作用研究进展[J].中国中药杂志，2016，41（2）：167-176.
[20] 左爱华，王莉，肖红斌.藁本内酯药理学和药代动力学研究进展[J].中国中药杂志，2012，37（22）：3350-3353.
[21] 杨志军，顾宁.藁本内酯心血管药理作用研究概况[J].吉林中医药，2016，36（2）：211-213. |
|
|
|
